A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's ...
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Incyte also declined after study data disappointed investors. Shares of Sarepta Therapeutics plunged earlier in the week after it reported the death of a patient after treatment with Elevidys ...
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Incyte shares declined after the announcement of data from two late-stage studies on an oral small-molecule JAK1 ...
Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...
Incyte (NASDAQ:INCY – Get Free Report) had its target price dropped by equities research analysts at Morgan Stanley from $69.00 to $65.00 in a research report issued to clients and investors on ...
Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company specializing in oncology and dermatology, finds itself at a critical juncture as it navigates the impending loss of patent protection ...
Thrivent Financial for Lutherans boosted its holdings in Incyte Co. (NASDAQ:INCY – Free Report) by 314.3% during the fourth quarter, Holdings Channel.com reports.The firm owned 30,377 shares of ...
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback